cancer-therapy-and-biomarkers-2016_tracks-abstracts

28 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 59
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Gut microbiota modulates cisplatin mediated systemic toxicity
Soumen Roy1, Rodrigo Das Neves1, Carolyne Smith1, Bathai Edwards1, Amiran Dzutsev1, Loretta Smith2, Simone Difilippantonio2, Lake Ross3, Susan
Garfield4, Poonam Mannan4, Lim Langston4, Hawes Misty2, Ren Ming Dai1, Sharon Bargo1, Young Kim and Giorgio Trinchieri1,2
1Cancer and Inflammation Program, NCI, NIH, USA
2Cancer and Inflammation Program, NCI, NIH, USA
3Laboratory of Genitourinary Cancer Pathogenesis, NCI, USA
4Confocal Core, CCR, NCI, NIH, USA
5Division of Cancer prevention, NCI, NIH, USA
Anticancer chemotherapy has achieved a significant milestone in increasing the number of cancer survivors over past decades,
while leaving behind the survivors with various toxic side effects, which are nephrotoxicity, ototoxicity and intestinal damage.
Challenges remain to reduce systemic toxicity as well as retaining the anticancer therapy. Gut microbiota modulates cancer
chemotherapy, however little is known about the role of gut microbiota in modulating systemic toxicity. We hypothesized that
gut microbiota regulates systemic toxicity. Four groups (n=10/group) of 8 weeks old C57B/6 mice were treated with cisplatin,
cisplatin+antibiotics cocktails (ABX), ABX only and untreated. ABX cocktail contained primaxin, vancomycin and neomycin,
which depletes broad spectrum gut microbiota. This experiment was validated using C57B/6 germ free mice (contains no
microorganisms). We performed anti-p-γ-H2AX and anti-ATM based DNA-double stranded break (stains foci in the nuclei)
based toxicity assay in kidney and gut (small bowel). H&E and 4 color immunostaining (anti-p-γ-H2AX, anti-ATM, Actin and
DAPI) were done. DNA-DSBs were evaluated using Zeiss 780 confocal and quantified by 3-D reconstruction using IMARIS.
There were reductions in γ-H2AX+ DAPI+ (DNA damaged) cell populations compared to only cisplatin treated mice, indicated
protection in the kidney. Both nuclear foci counts as well as the pathological scores indicated gut microbiota associated modu-
lation in the glomeruli of kidney and in the villi of small bowel. Our data leads to a possibility to develop microbiota based ther-
apy which might be utilized to reduce chemotherapy associated systemic toxicity and for better management of chemotherapy.
Biography
Roy is currently working in the field of cancer and gut microbiota at the National Cancer Institute (NCI), NIH in the laboratory of Dr. Giorgio Trinchieri. His main focus
is to investigate the role of gut microbiota in chemotherapeutic drug and radiation therapy induced local and systemic toxicity. Prior joining the National Cancer
Institute, Dr. Roy worked at the National Institutes on Deafness and other Communication Disorders (NIDCD) in the Laboratory of Dr. Lisa Cunningham, where he
contributed to the development of a sound conditioning based co-therapy, which inhibits cisplatin and aminoglycoside mediated hearing loss in mice. Roy received
his doctorate degree under the supervision of Anneliese Schrott Fischer in the field of targeted nanomedicine and hearing from University of Innsbruck, Austria in
2011
Soumen Roy et al., Oncol Cancer Case Rep 2016,2:3(Suppl)